Back to search
Central Retinal Vein Occlusion
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Central Retinal Vein Occlusion trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Central Retinal Vein Occlusion trials you may qualify forCD160 represents a new angiogenic factor as its specific engagement by an agonist monoclonal antibody directed against human CD160 reduced angiogenesis of endot…
Bevacizumab, an anti-VEGF (vascular endothelial growth factor) agent used in the treatment of diabetic retinopathy and macular edema associated with retinal vei…
The main goal of this study is to find out how common certain eye diseases are in Germany and how they have changed over time. The diseases being studied are:…
Background: \- To understand diseases of the retina and the eye, information is needed about people with and without such diseases. Researchers want to study t…
This study will perform a prospective, longitudinal analysis of clinical and imaging findings from normal controls and subjects with retinal vascular disease to…
Retinal vein occlusion (RVO), a common retinal vascular disease, is frequently treated with anti-vascular endothelial growth factor (anti-VEGF) agents as first-…
Intravitreal injections of Ranibizumab will be applied in all patients according to treatment guidelines. The experimental group will receive additional targete…
This study will evaluate the effectiveness of hyperbaric oxygen therapy (HBOT) on treating emerging indications (i.e., conditions that have shown to potentially…